Home›Trial›NCT07073690
NCT07073690Completed

Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China

Study Summary

The purpose of this study is to evaluate the treatment patterns and clinical outcomes in adults with lower-risk MDS (LR-MDS) who were erythropoiesis-stimulating agents (ESA)-naïve and received luspatercept treatment in China

Conditions
Myelodysplastic Syndromes
Interventions / Drugs
Luspatercept
View on ClinicalTrials.gov ↗
Sponsor
BMY
Bristol-Myers Squibb
Oncology
C51/100
Study Details
Enrollment88 participants
Primary Completion2026-05-12
Lead SponsorBristol-Myers Squibb
Data Retrieved2026-10-14
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

This trial has completed. Results may be available via ClinicalTrials.gov or peer-reviewed publications.

Primary completion: 2026-05-12
Enrolled: 88 participants
Sponsor Catalyst Profile

Bristol-Myers Squibb (BMY) is the sponsoring company for this trial. BiotechSign currently grades this company C (51/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

BMY Full Pipeline →All Companies →
Other Trials from Bristol-Myers Squibb
NCT07215962Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non…NCT05489705A Prospective Registry Study to Assess Real-world Patient Characteristics, Treat…NCT07063342A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC …(PHASE1)NCT06937229A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agi…(PHASE3)NCT06003426A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Part…(PHASE3)
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.
© 2026 BiotechSign — AI-powered biotech catalyst intelligence